Showing results (1021-1030 of 1,065) with videos related to

Sort By:
Pageof 107
Gut|July 19, 2023
Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg)Ángeles Pérez-Aisa, Olga P Nyssen, Alma Keco-Huerga, et al.
Therapeutic Advances in Gastroenterology|January 8, 2024
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registryMargalida Calafat, Paola Torres, Joan Tosca-Cuquerella, et al.
Plos Genetics|July 28, 2010
Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locusSimon N Stacey, Patrick Sulem, Carlo Zanon, et al.
Inflammatory Bowel Diseases|September 11, 2019
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida RegistryMaría José Casanova, María Chaparro, Miguel Mínguez, et al.
Alimentary Pharmacology & Therapeutics|June 10, 2026
Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA RegistryManuel Barreiro-de Acosta, Yamile Zabana, Laura Nieto-García, et al.
Cell Metabolism|August 1, 2023
Hepatic levels of S-adenosylmethionine regulate the adaptive response to fastingAlba Capelo-Diz, Sofía Lachiondo-Ortega, David Fernández-Ramos, et al.
Revista Espanola De Salud Publica|December 16, 2020
[50 years of the Neonatal Screening Program in Catalonia.]Jose Luis Marín Soria, Rosa Mª López Galera, Ana Argudo Ramírez, et al.
Inflammatory Bowel Diseases|February 15, 2022
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN StudyMaría Chaparro, Iria Baston-Rey, Estela Fernández-Salgado, et al.
Journal of Clinical Medicine|August 12, 2022
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on UstekinumabMaría Chaparro, Iria Baston-Rey, Estela Fernández Salgado, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2025
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDACristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, et al.
Pageof 107